SGLT-2 Inhibitor and GLP-1 Receptor Agonist Treatment for Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Is Their Combination the Optimal Treatment Option?

Detalles Bibliográficos
Autores principales: Patoulias, Dimitrios, Michailidis, Theodoros
Formato: Online Artículo Texto
Lenguaje:English
Publicado: XIA & HE Publishing Inc. 2022
Materias:
Hot Topic Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396330/
https://www.ncbi.nlm.nih.gov/pubmed/36062276
http://dx.doi.org/10.14218/JCTH.2022.00278
_version_ 1784771907608903680
author Patoulias, Dimitrios
Michailidis, Theodoros
author_facet Patoulias, Dimitrios
Michailidis, Theodoros
author_sort Patoulias, Dimitrios
collection PubMed
description
format Online
Article
Text
id pubmed-9396330
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher XIA & HE Publishing Inc.
record_format MEDLINE/PubMed
spelling pubmed-93963302022-09-02 SGLT-2 Inhibitor and GLP-1 Receptor Agonist Treatment for Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Is Their Combination the Optimal Treatment Option? Patoulias, Dimitrios Michailidis, Theodoros J Clin Transl Hepatol Hot Topic Commentary XIA & HE Publishing Inc. 2022-08-28 2022-07-13 /pmc/articles/PMC9396330/ /pubmed/36062276 http://dx.doi.org/10.14218/JCTH.2022.00278 Text en © 2022 Authors. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-Noncommercial 4.0 International License (CC BY-NC 4.0), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Hot Topic Commentary
Patoulias, Dimitrios
Michailidis, Theodoros
SGLT-2 Inhibitor and GLP-1 Receptor Agonist Treatment for Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Is Their Combination the Optimal Treatment Option?
title SGLT-2 Inhibitor and GLP-1 Receptor Agonist Treatment for Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Is Their Combination the Optimal Treatment Option?
title_full SGLT-2 Inhibitor and GLP-1 Receptor Agonist Treatment for Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Is Their Combination the Optimal Treatment Option?
title_fullStr SGLT-2 Inhibitor and GLP-1 Receptor Agonist Treatment for Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Is Their Combination the Optimal Treatment Option?
title_full_unstemmed SGLT-2 Inhibitor and GLP-1 Receptor Agonist Treatment for Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Is Their Combination the Optimal Treatment Option?
title_short SGLT-2 Inhibitor and GLP-1 Receptor Agonist Treatment for Patients with Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Is Their Combination the Optimal Treatment Option?
title_sort sglt-2 inhibitor and glp-1 receptor agonist treatment for patients with nonalcoholic fatty liver disease and type 2 diabetes mellitus: is their combination the optimal treatment option?
topic Hot Topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9396330/
https://www.ncbi.nlm.nih.gov/pubmed/36062276
http://dx.doi.org/10.14218/JCTH.2022.00278
work_keys_str_mv AT patouliasdimitrios sglt2inhibitorandglp1receptoragonisttreatmentforpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitusistheircombinationtheoptimaltreatmentoption
AT michailidistheodoros sglt2inhibitorandglp1receptoragonisttreatmentforpatientswithnonalcoholicfattyliverdiseaseandtype2diabetesmellitusistheircombinationtheoptimaltreatmentoption

Ejemplares similares